Table 1.
Baseline clinical, radiological and histopathological characteristics of the cohort with composite h-scores stratified on the basis of demographic characteristics.
| Parameter | pEGFR T693 h-score | p-value | ||
|---|---|---|---|---|
| Range (Min-Max) | Mean ± SD | |||
| Age | <30 years (n=11) | 7.05-201.1 | 82.2 ± 17.1 | 0.67 |
| 30-50 years (n=69) | 11.5-227.4 | 94.3 ± 17.1 | ||
| >50 years (n=22) | 41.8-166.6 | 94.0 ± 7.0 | ||
| Gender | Female (n=37) | 13.8-227.4 | 93.9 ± 7.5 | 0.99 |
| Male (n=65) | 7.0-209.3 | 93.1 ± 5.0 | ||
| Tumor diameter | Giant (n=47) | 7.0-227.4 | 90.7 ± 6.9 | 0.57 |
| Macro (n=55) | 11.5-209.3 | 95.6 ± 5.0 | ||
| Tumor volume | Above median (14000mm3) | 7.0-209.3 | 92.3 ± 5.3 | 0.88 |
| Below median (14000mm3) | 11.5-227.4 | 92.3 ± 6.6 | ||
| Tumor extension | Intrasellar (n=30) | 49.9-209.3 | 93.6 ± 7.3 | 0.47 |
| SSE (n=46) | 11.5-201.1 | 86.3 ± 5.7 | ||
| SSE+PSE (n=16) | 41-166.6 | 96.0 ± 9.8 | ||
| SSE+PSE+ISE (n=6) | 7.0-227.4 | 119.3 ± 30.8 | ||
| SSE+ISE (n=4) | 64.4-158.2 | 94.7 ± 21.7 | ||
| Clinico-pathological grading by Trouillas et al | 1a (n=44) | 11.5-201.1 | 81.8 ± 5.8 | 0.05 |
| 1b (n=7) | 101-158 | 130.7 ± 9.2 | ||
| 2a (n=43) | 7.0-227.4 | 95.6 ± 6.2 | ||
| 2b (n=8) | 13.8-178.8 | 128.4 ± 10.7 | ||
| 1a+2a (n=87) | 7.0-227.4 | 89.1 ± 4.3 | 0.02* | |
| 1b+2b (n=15) | 13.8-178.8 | 116.2 ± 11.0 | ||
| IHC | Silent Adenomas (n=21) | 32.7-201.1 | 105.1 ± 9.0 | 0.15 |
| Gonadotropinomas (n=72) | 13.8-227.4 | 91.1 ± 4.8 | ||
| Null Cell adenomas (n=9) | 7.0-141 | 73.6 ± 14.3 | ||
| Recurrence | Recurrent (n=47) | 34.6-227.4 | 117 ± 6.0 | <0.0001**** |
| Non-recurrent (n=55) | 7.0-144.4 | 71.2 ± 3.7 | ||
Data are presented as range or mean ± SD.
SSE, suprasellar extension; PSE, parasellar extension; ISE, infrasellar extension; IHC, immunohistochemistry.
*significant, ****highly significant.
The bold values refer to significant parameters.